LataMed AI Corp. (OTC: LMEDD) announced today that its previously announced 5-for-1 forward stock split has become effective at the opening of trading, following the publication of the corporate action on the FINRA Daily List dated July 14, 2026. The company's common stock began trading today under the temporary trading symbol LMEDD, with the 'D' designation serving as a standard FINRA identifier for corporate actions. This temporary symbol is expected to remain in place for approximately twenty business days, after which the trading symbol is expected to revert to LMED.
The forward stock split has been implemented in conjunction with the company's mandatory share exchange and a new CUSIP number, 21116R404. As a result, the prior CUSIP number, 21116R305, has been suspended effective upon market effectiveness of the split. This move is part of LataMed AI's broader strategy to streamline its capital structure and support its long-term growth objectives.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: 'Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms.'
The company reminded shareholders that those holding shares through brokerage accounts or in electronic book-entry form generally are not required to take any action, as brokerage firms, custodians, and other market participants are expected to process the corporate action automatically through the normal securities settlement process. Shareholders holding physical stock certificates are not required to immediately surrender their certificates, but when presented to the company's transfer agent for transfer, sale, or exchange, they will be processed in accordance with the mandatory exchange procedures and exchanged for the appropriate number of post-split shares under the new CUSIP.
LataMed AI is a development-stage digital health and artificial intelligence technology company focused on building telehealth infrastructure, healthcare coordination tools, analytics capabilities, and AI-enabled healthcare solutions for emerging markets, with an initial regional focus on Latin America. The forward stock split is intended to support the company's efforts to enhance shareholder value and facilitate the execution of its business plan.
For additional information, the company encourages shareholders to visit https://latamed.ai, follow its official social media channels, or review its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
